India is manufacturing AstraZeneca and other vaccines for export. Prior pandemic India manufactured 2.3 billion vaccines annually. Patent fees are big part of expenses.
RNA based experiments are doable in most university labs. It is 2021.
RNA based experiments are doable in most university labs. It is 2021.
There is a huge difference between doing RNA experiments versus manufacturing millions of doses of mRNA vaccine without errors or contamination.
The approach to intellectual property in China is much more open, partly because the leaders understand that technical expertise is more than just a one-off design, and competitors probably can't enter the market without significant capital investment and risk. In the case of healthcare, I suspect that regulators will prevent any vaccines manufactured with sub-standard procedures, such as those made in university labs.